Multiple Sclerosis Discovery Forum

Inspiring Connections

Most Viewed Papers

Therapeutic class review, Neurological - multiple sclerosis dalfampridine (Ampyra(TM))
Genome-wide meta-analysis identifies novel multiple sclerosis susceptibility loci.
Receptos to deliver scientific presentations about RPC1063 at the 28th Congress of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS)
Roche reports positive studies of MabThera given by subcutaneous injection
Varicella-Zoster Virus Infections in Patients Treated With Fingolimod: Risk Assessment and Consensus Recommendations for Management.
Pooled safety and tolerability data from four placebo-controlled teriflunomide studies and extensions.
Fourth PML Case With Tecfidera in MS Calls for Vigilance
Drak2 Does Not Regulate TGF-β Signaling in T Cells.
Receptos Initiates SUNBEAM Phase 3 Trial of RPC1063 in Relapsing Multiple Sclerosis
FDA denies Teva Copaxone generic trials petition
Sphingosine and FTY720 are potent inhibitors of the transient receptor potential melastatin 7 (TRPM7) channels.
Cortical demyelination and diffuse white matter injury in multiple sclerosis.
Voltage-gated potassium channels in multiple sclerosis: Overview and new implications for treatment of central nervous system inflammation and degeneration.
The potential teratogenic effects of interferon beta-1a (IFNβ-1a) and interferon beta-1b (IFNβ-1b) on in vitro embryonic development.
FDA Accepts Filing of BETACONNECT™* for Relapsing-Remitting Multiple Sclerosis Patients Taking BETASERON® (interferon beta-1b)
High dose cyclophosphamide preferentially targets naïve T (CD45/CD4/RA+) cells in CIDP and MS patients.
Quantitative assays for anti-aquaporin-4 antibody with subclass analysis in neuromyelitis optica.
Efficacy and safety study of RPC1063 in relapsing multiple sclerosis patients
Laquinimod Study in Systemic Lupus Erythematosus (SLE) Patients With Active Lupus Nephritis
Predictive value of early brain atrophy on response in patients treated with interferon β.
Impact of cladribine therapy on changes in circulating dendritic cell subsets, T cells and B cells in patients with multiple sclerosis.
Multiple sclerosis: an immune or neurodegenerative disorder?
Assessment of statistical significance and clinical relevance.
Genmab Announces Ofatumumab Development Plans in RRMS and NMO
Enzon presents pre-clinical data on controlled release of PEGylated interferon-beta-1b and PEGylated anti-TNF-a antibody fragment at the Controlled Release Society annual meeting

Pages